Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline.

Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, Lee YCG, Lewis SZ, Maskell NA, Rahman NM, Sterman DH, Wahidi MM, Balekian AA.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):839-849. doi: 10.1164/rccm.201807-1415ST.

PMID:
30272503
2.

Investigating unilateral pleural effusions: the role of cytology.

Arnold DT, De Fonseka D, Perry S, Morley A, Harvey JE, Medford A, Brett M, Maskell NA.

Eur Respir J. 2018 Nov 8;52(5). pii: 1801254. doi: 10.1183/13993003.01254-2018. Print 2018 Nov.

PMID:
30262573
3.

Local Anaesthetic (Medical) Thoracoscopy Services in the UK.

de Fonseka D, Bhatnagar R, Maskell NA.

Respiration. 2018 Sep 10:1-4. doi: 10.1159/000491674. [Epub ahead of print]

PMID:
30199872
4.

Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial.

de Fonseka D, Morley A, Stadon L, Keenan E, Walker S, Smith S, Harvey JE, Cox RA, Dangoor A, Comins C, Rogers C, Edey A, Addeo A, Maskell NA.

Trials. 2018 Aug 29;19(1):467. doi: 10.1186/s13063-018-2851-9.

5.

Current treatments and trials in malignant pleural mesothelioma.

Bibby AC, Maskell NA.

Clin Respir J. 2018 Jul;12(7):2161-2169. doi: 10.1111/crj.12938.

PMID:
30129116
6.

ERS/EACTS statement on the management of malignant pleural effusions.

Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Maskell NA, Cardillo G.

Eur J Cardiothorac Surg. 2018 Jul 27. doi: 10.1093/ejcts/ezy258. [Epub ahead of print] No abstract available.

PMID:
30060030
7.

ERS/EACTS statement on the management of malignant pleural effusions.

Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Cardillo G, Maskell NA.

Eur Respir J. 2018 Jul 27;52(1). pii: 1800349. doi: 10.1183/13993003.00349-2018. Print 2018 Jul.

PMID:
30054348
8.

Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial.

Muruganandan S, Azzopardi M, Fitzgerald DB, Shrestha R, Kwan BCH, Lam DCL, De Chaneet CC, Rashid Ali MRS, Yap E, Tobin CL, Garske LA, Nguyen PT, Stanley C, Popowicz ND, Kosky C, Thomas R, Read CA, Budgeon CA, Feller-Kopman D, Maskell NA, Murray K, Lee YCG.

Lancet Respir Med. 2018 Sep;6(9):671-680. doi: 10.1016/S2213-2600(18)30288-1. Epub 2018 Jul 20.

PMID:
30037711
9.

Are intra-pleural bacterial products associated with longer survival in adults with malignant pleural effusions? A systematic review.

Bibby AC, Walker S, Maskell NA.

Lung Cancer. 2018 Aug;122:249-256. doi: 10.1016/j.lungcan.2018.06.002. Epub 2018 Jun 11.

10.

Recurrence rates in primary spontaneous pneumothorax: a systematic review and meta-analysis.

Walker SP, Bibby AC, Halford P, Stadon L, White P, Maskell NA.

Eur Respir J. 2018 Sep 6;52(3). pii: 1800864. doi: 10.1183/13993003.00864-2018. Print 2018 Sep.

PMID:
30002105
11.

An Inconvenient Truth Concerning Surgery for Mesothelioma.

de Fonseka D, Slade M, Blyth KG, Edwards J, Evison M, Roberts M, Rahman N, Woolhouse I, Maskell NA.

J Clin Oncol. 2018 Sep 10;36(26):2745-2746. doi: 10.1200/JCO.2018.78.6590. Epub 2018 Jun 14. No abstract available.

PMID:
29902107
12.

Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion.

Bhatnagar R, Keenan EK, Morley AJ, Kahan BC, Stanton AE, Haris M, Harrison RN, Mustafa RA, Bishop LJ, Ahmed L, West A, Holme J, Evison M, Munavvar M, Sivasothy P, Herre J, Cooper D, Roberts M, Guhan A, Hooper C, Walters J, Saba TS, Chakrabarti B, Gunatilake S, Psallidas I, Walker SP, Bibby AC, Smith S, Stadon LJ, Zahan-Evans NJ, Lee YCG, Harvey JE, Rahman NM, Miller RF, Maskell NA.

N Engl J Med. 2018 Apr 5;378(14):1313-1322. doi: 10.1056/NEJMoa1716883.

13.

Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial).

de Fonseka D, Underwood W, Stadon L, Rahman N, Edey A, Rogers C, Maskell NA.

BMJ Open Respir Res. 2018 Feb 19;5(1):e000270. doi: 10.1136/bmjresp-2017-000270. eCollection 2018.

14.

BTS guideline for the investigation and management of malignant pleural mesothelioma.

Woolhouse I, Bishop L, Darlison L, de Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, Nakas A, Peel T, Rahman NM, Slade M, Steele J, Tsim S, Maskell NA.

BMJ Open Respir Res. 2018 Feb 14;5(1):e000266. doi: 10.1136/bmjresp-2017-000266. eCollection 2018.

15.

The role of procalcitonin in the management of pleural infection.

de Fonseka D, Maskell NA.

Curr Opin Pulm Med. 2018 Jul;24(4):380-383. doi: 10.1097/MCP.0000000000000481.

PMID:
29528854
16.

A Pilot Feasibility Study in Establishing the Role of Ultrasound-Guided Pleural Biopsies in Pleural Infection (The AUDIO Study).

Psallidas I, Kanellakis NI, Bhatnagar R, Ravindran R, Yousuf A, Edey AJ, Mercer RM, Corcoran JP, Hallifax RJ, Asciak R, Shetty P, Dong T, Piotrowska HEG, Clelland C, Maskell NA, Rahman NM.

Chest. 2018 Oct;154(4):766-772. doi: 10.1016/j.chest.2018.02.031. Epub 2018 Mar 7.

PMID:
29524388
17.

A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.

de Fonseka D, Arnold DT, Stadon L, Morley A, Keenan E, Darby M, Armstrong L, Virgo P, Maskell NA.

BMC Cancer. 2018 Feb 17;18(1):199. doi: 10.1186/s12885-018-4113-3.

18.

Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma.

Woolhouse I, Maskell NA.

Thorax. 2018 Mar;73(3):210-212. doi: 10.1136/thoraxjnl-2017-211416. No abstract available.

PMID:
29444989
19.

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma.

Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, Nakas A, Peel T, Rahman NM, Slade M, Steele J, Tsim S, Maskell NA.

Thorax. 2018 Mar;73(Suppl 1):i1-i30. doi: 10.1136/thoraxjnl-2017-211321. No abstract available.

PMID:
29444986
20.

Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial.

Stewart SA, Clive AO, Maskell NA, Penz E.

PLoS One. 2018 Feb 5;13(2):e0190257. doi: 10.1371/journal.pone.0190257. eCollection 2018.

21.

Commentary: considerations for using the 'Trials within Cohorts' design in a clinical trial of an investigational medicinal product.

Bibby AC, Torgerson DJ, Leach S, Lewis-White H, Maskell NA.

Trials. 2018 Jan 8;19(1):18. doi: 10.1186/s13063-017-2432-3.

22.

18F-Fluorodeoxyglucose PET/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma.

Hall DO, Hooper CE, Searle J, Darby M, White P, Harvey JE, Braybrooke JP, Maskell NA, Masani V, Lyburn ID.

Nucl Med Commun. 2018 Feb;39(2):161-170. doi: 10.1097/MNM.0000000000000789.

PMID:
29300270
23.

Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study.

Bibby AC, De Fonseka D, Morley AJ, Keenan E, Addeo A, Smith S, Edey AJ, Maskell NA.

BMC Palliat Care. 2017 Dec 8;16(1):71. doi: 10.1186/s12904-017-0255-3.

24.

A Prospective Study to Evaluate a Diagnostic Algorithm for the Use of Fluid Lymphocyte Subset Analysis in Undiagnosed Unilateral Pleural Effusions.

Dixon G, Bhatnagar R, Zahan-Evans N, Clive AO, Virgo PF, Brett MT, Otton SH, Medford ARL, Maskell NA.

Respiration. 2018;95(2):98-105. doi: 10.1159/000481290. Epub 2017 Nov 10.

PMID:
29131120
25.

Benign pleural schwannoma presenting with a large, blood-stained pleural effusion.

Bibby AC, Daly R, Internullo E, Edey AJ, Maskell NA.

Thorax. 2018 May;73(5):497-498. doi: 10.1136/thoraxjnl-2017-211102. Epub 2017 Nov 9. No abstract available.

PMID:
29123017
26.

Conservative Management in Traumatic Pneumothoraces: An Observational Study.

Walker SP, Barratt SL, Thompson J, Maskell NA.

Chest. 2018 Apr;153(4):946-953. doi: 10.1016/j.chest.2017.10.015. Epub 2017 Nov 15.

PMID:
29080710
27.

Biomarkers in mesothelioma.

Arnold DT, Maskell NA.

Ann Clin Biochem. 2018 Jan;55(1):49-58. doi: 10.1177/0004563217741145. Epub 2017 Nov 13. Review.

PMID:
29058958
28.

Pneumothorax management: time to improve the evidence base.

Maskell NA.

Thorax. 2017 Dec;72(12):1065-1066. doi: 10.1136/thoraxjnl-2017-211007. Epub 2017 Sep 25. No abstract available.

PMID:
28947668
29.

Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion.

Mishra EK, Clive AO, Wills GH, Davies HE, Stanton AE, Al-Aloul M, Hart-Thomas A, Pepperell J, Evison M, Saba T, Harrison RN, Guhan A, Callister ME, Sathyamurthy R, Rehal S, Corcoran JP, Hallifax R, Psallidas I, Russell N, Shaw R, Dobson M, Wrightson JM, West A, Lee YCG, Nunn AJ, Miller RF, Maskell NA, Rahman NM.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):502-508. doi: 10.1164/rccm.201704-0809OC.

PMID:
28926296
30.

The physiological consequences of different distributions of diffuse pleural thickening on CT imaging.

de Fonseka D, Edey A, Stadon L, Viner J, Darby M, Maskell NA.

Br J Radiol. 2017 Aug;90(1077):20170218. doi: 10.1259/bjr.20170218. Epub 2017 Jul 14.

31.

A Novel Drug-Eluting Indwelling Pleural Catheter for the Management of Malignant Effusions.

Bhatnagar R, Zahan-Evans N, Kearney C, Edey AJ, Stadon LJ, Tremblay A, Maskell NA.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):136-138. doi: 10.1164/rccm.201701-0097LE. No abstract available.

PMID:
28574275
32.

Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.

Arnold DT, De Fonseka D, Hamilton FW, Rahman NM, Maskell NA.

Br J Cancer. 2017 Mar 14;116(6):731-741. doi: 10.1038/bjc.2017.22. Epub 2017 Feb 7. Review.

33.

The role of serum procalcitonin in establishing the diagnosis and prognosis of pleural infection.

Dixon G, Lama-Lopez A, Bintcliffe OJ, Morley AJ, Hooper CE, Maskell NA.

Respir Res. 2017 Feb 3;18(1):30. doi: 10.1186/s12931-017-0501-5.

34.

Nonmalignant Pleural Effusions: A Prospective Study of 356 Consecutive Unselected Patients.

Walker SP, Morley AJ, Stadon L, De Fonseka D, Arnold DT, Medford ARL, Maskell NA.

Chest. 2017 May;151(5):1099-1105. doi: 10.1016/j.chest.2016.12.014. Epub 2016 Dec 23.

PMID:
28025056
35.

Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.

Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, Psallidas I.

Eur Respir Rev. 2016 Dec;25(142):472-486. doi: 10.1183/16000617.0063-2016. Review.

36.

Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study.

Tsim S, Kelly C, Alexander L, McCormick C, Thomson F, Woodward R, Foster JE, Stobo DB, Paul J, Maskell NA, Chalmers A, Blyth KG.

BMJ Open. 2016 Nov 24;6(11):e013324. doi: 10.1136/bmjopen-2016-013324.

37.

Current best practice in the evaluation and management of malignant pleural effusions.

Walker S, Bibby AC, Maskell NA.

Ther Adv Respir Dis. 2017 Feb;11(2):105-114. doi: 10.1177/1753465816671697. Epub 2016 Oct 24. Review.

38.

Prophylactic radiotherapy to prevent procedure-tract metastases - Author's reply.

Clive AO, Taylor H, Maskell NA.

Lancet Oncol. 2016 Oct;17(10):e419. doi: 10.1016/S1470-2045(16)30454-5. No abstract available.

PMID:
27733265
39.

What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK.

Bibby AC, Williams K, Smith S, Bhatt N, Maskell NA.

BMJ Open. 2016 Sep 8;6(9):e012092. doi: 10.1136/bmjopen-2016-012092.

40.

The management of benign non-infective pleural effusions.

Bintcliffe OJ, Lee GY, Rahman NM, Maskell NA.

Eur Respir Rev. 2016 Sep;25(141):303-16. doi: 10.1183/16000617.0026-2016. Review.

41.

Primary spontaneous pneumothorax: a cohort study of VATS with talc poudrage.

Cardillo G, Bintcliffe OJ, Carleo F, Carbone L, Di Martino M, Kahan BC, Maskell NA.

Thorax. 2016 Sep;71(9):847-53. doi: 10.1136/thoraxjnl-2015-207976. Epub 2016 Jul 15.

PMID:
27422793
42.

Cochrane corner: interventions for the management of malignant pleural effusions.

Clive AO, Bhatnagar R, Preston NJ, Maskell NA, Jones HE.

Thorax. 2016 Oct;71(10):964-6. doi: 10.1136/thoraxjnl-2016-208989. Epub 2016 Jul 14.

PMID:
27418604
43.

Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters.

Azzopardi M, Thomas R, Muruganandan S, Lam DC, Garske LA, Kwan BC, Rashid Ali MR, Nguyen PT, Yap E, Horwood FC, Ritchie AJ, Bint M, Tobin CL, Shrestha R, Piccolo F, De Chaneet CC, Creaney J, Newton RU, Hendrie D, Murray K, Read CA, Feller-Kopman D, Maskell NA, Lee YC.

BMJ Open. 2016 Jul 5;6(7):e011480. doi: 10.1136/bmjopen-2016-011480.

44.

Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial.

Clive AO, Taylor H, Dobson L, Wilson P, de Winton E, Panakis N, Pepperell J, Howell T, Stewart SA, Penz E, Jordan N, Morley AJ, Zahan-Evans N, Smith S, Batchelor TJP, Marchbank A, Bishop L, Ionescu AA, Bayne M, Cooper S, Kerry A, Jenkins P, Toy E, Vigneswaran V, Gildersleve J, Ahmed M, McDonald F, Button M, Lewanski C, Comins C, Dakshinamoorthy M, Lee YCG, Rahman NM, Maskell NA.

Lancet Oncol. 2016 Aug;17(8):1094-1104. doi: 10.1016/S1470-2045(16)30095-X. Epub 2016 Jun 23.

45.

Unilateral Pleural Effusions with More Than One Apparent Etiology. A Prospective Observational Study.

Bintcliffe OJ, Hooper CE, Rider IJ, Finn RS, Morley AJ, Zahan-Evans N, Harvey JE, Skyrme-Jones AP, Maskell NA.

Ann Am Thorac Soc. 2016 Jul;13(7):1050-6. doi: 10.1513/AnnalsATS.201601-082OC.

PMID:
27064965
46.

Pleural biopsies in undiagnosed pleural effusions; Abrams vs image-guided vs thoracoscopic biopsies.

Bibby AC, Maskell NA.

Curr Opin Pulm Med. 2016 Jul;22(4):392-8. doi: 10.1097/MCP.0000000000000258. Review.

PMID:
27055071
47.

Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial.

Rahman NM, Pepperell J, Rehal S, Saba T, Tang A, Ali N, West A, Hettiarachchi G, Mukherjee D, Samuel J, Bentley A, Dowson L, Miles J, Ryan CF, Yoneda KY, Chauhan A, Corcoran JP, Psallidas I, Wrightson JM, Hallifax R, Davies HE, Lee YC, Dobson M, Hedley EL, Seaton D, Russell N, Chapman M, McFadyen BM, Shaw RA, Davies RJ, Maskell NA, Nunn AJ, Miller RF.

JAMA. 2015 Dec 22-29;314(24):2641-53. doi: 10.1001/jama.2015.16840. Erratum in: JAMA. 2016 Feb 16;315(7):707. JAMA. 2016 Apr 19;315(15):1661.

PMID:
26720026
48.

Lung Parenchymal Assessment in Primary and Secondary Pneumothorax.

Bintcliffe OJ, Edey AJ, Armstrong L, Negus IS, Maskell NA.

Ann Am Thorac Soc. 2016 Mar;13(3):350-5. doi: 10.1513/AnnalsATS.201509-584OC.

PMID:
26710080
49.

Evaluation of an ambulatory pleural service: costs and benefits.

Young RL, Bhatnagar R, Medford AR, Maskell NA.

Br J Hosp Med (Lond). 2015 Oct;76(10):608. doi: 10.12968/hmed.2015.76.10.608. No abstract available.

PMID:
26457948
50.

Absence of Atypical Pathogens in Pleural Infection.

Wrightson JM, Wray JA, Street TL, Chapman SJ, Gleeson FV, Maskell NA, Peto TEA, Rahman NM, Crook DWM.

Chest. 2015 Sep;148(3):e102-e103. doi: 10.1378/chest.15-1130. No abstract available.

PMID:
26324137

Supplemental Content

Loading ...
Support Center